MOHAMED SAMY AYISH
Jeddah,Saudi Arabia
Summary
Senior medical Science Liaison at Boehringer Ingelheim, Saudi Arabia, Gulf countries and East Africa. With over 10 years of experience in the pharmaceutical industry, including 7 years in medical affairs across Saudi Arabia and the Gulf countries. Proven expertise in leading strategic medical initiatives and facilitating patient access to innovative therapies. Successfully led the pre-launch and launch of three new indications for Empagliflozin, supporting their market entry in Saudi Arabia and the Gulf region. Skilled in developing and executing medical plans, navigating regulatory processes, and collaborating with key stakeholders to ensure the optimal use of scientific evidence and medical education. Committed to advancing patient outcomes through evidence-based strategies, cross-functional collaboration, and impactful access programs.
Overview
12
12
years of professional experience
5
5
years of post-secondary education
Work history
Senior Medical Science Liaison
Boehringer Ingelheim
2025.03 - 2026.03
- Prelaunch Obesity and MASH indication for Survodutide (currently phase III molecule)
- Support pre-launch readiness activities, contribute ICP plans, and ensure robust launch preparation across countries.
- Leading and executing ICP plan for Survodutide
- Collecting and constructing structure medical insights to cover the currents gaps and unmet needs in obesity and MASH.
- Communication with EE phase II results.
- Manage and control the direct budget and spent for the team
- Medical governance accountability, ensure all activities are done for the respective adherence to the local regulations codes and company SOPs
Phase III Clinical Trials in Saudi Arabia
Boehringer Ingelheim
2024.01 - 2026.03
- Pipeline management support and early medical affairs role.
- Clinical trials conduction support (support the regional clinical trial operation team to initiate the trial sites, train them, and accelerate and follow up on the inclusion and minimize the dropout%).
- These trials are:
- 1- SYNCRONIZE CVOT obesity.
- 2- LEVERAGE & LEVERAGE-CIRRHOSIS for MASH.
- 3- EASI-PROTECT CVOT for EMPA-VICA.
- 4- EASI HFrEF and EASI HFmEF for EMPA-VICA.
Key Medical projects
Company Name
2023.01 - 2026.03
- CKD Path: Project with SSDS aimed at developing an AI risk assessment tool to enhance CKD diagnosis in Saudi Arabia targeting MODA and private hospitals.
- CKD consensus paper.
- Saudi Heart Failure guidelines updating.
- CKD Integrated Program (an educational platform for frontliners aimed at improving CKD early diagnosis and treatment).
- CV risk management consensus paper for Saudi Arabia and Gulf countries.
- Establishment of CRM clinic concept at two main hospitals IMC and Dallah
Medical Advisor and Healthcare Compliance Manager
Boehringer Ingelheim
2024.01 - 2025.03
- Provide strategic inputs to develop product life-cycle Management such as ICP and launch readiness towards ethical promotion of assigned products
- Managing the brand life cycle (pre-authorization, authorization, pre-launch, launch and post launch)
- Implement and execute short- and long-term medical goals and tactics, with an emphasis on pharmacotherapeutic aspects and with understanding of business priorities
- Developing and executing brand medical affairs plan
- Identifying evidence gaps and working with the brand team to address them
- Provide medical knowledge and scientific updates within the therapy area for external and internal stakeholders & scientific information management and dissemination
- Manage and control the direct budget and spend for the team
- Medical program execution as per IBP including medical grants; medical education; Advisory Board meeting and other consultancy activities
- Key Opinion Leader engagement: Identify KEES, establish and maintain KEE database with commercial partner; Build relationships with KEES to support clinical and research activities; Effective and scientific
Senior Medical Science Liaison
Boehringer Ingelheim
Jeddah
2021.09 - 2024.01
- Responsible for pre-launching and support in launching Empagliflozin's two new indications in heart failure with preserved ejection fraction HFpEF and chronic kidney diseases CKD indications
- Ensuring the pre-launching excellence in the new indications for Empagliflozin through accurately monitoring the launch readiness plan and ensuring excellence in its execution
- Participate and lead a local educational project in collaboration with local Saudi scientific societies which is a platform for educating the front-liners about the importance of early screening and diagnosis of CKD aimed for improving CKD management in Saudi Arabia and Gulf countries
- Participate in updating the local Saudi heart failure guidelines
- Support in the publication of the first local safety data for Empagliflozin PASS...Post Authorization Safety Study and lead its communication plan and its strategic implementation
- Scientific collaboration with selected healthcare professional (External experts) and local health care societies within the therapy area with the objectives of educational programs
- Responsible over the implementation of therapy area communication plans and management of targeted external experts through medical interaction and scientific exchange
- Timely respond to medical information requests from EE
- Document medical insights from daily interactions with HCPs which assists in building our strategy or modifying existing one
- Coaching of MSLs on excellence on customer engagement, activation of insights generation and assets management
- Internal training and maintaining scientific expertise within the cross functional team
- Competitor intelligence and sharing with the internal teams
- Ensures timely reporting of adverse events & assists local Pharmacovigilance team in completion of required data for optimal reporting
- Medical governance accountability, ensure all activities are done for the respective adherence to the local regulations codes and company SOPs
- Mapping and Identification of EEs in the country
- Develop and execute Integrated Customer Plan (ICP) to effectively prioritize and strategically engage EEs aligned with country Planned activity mapping for the identified EEs in the country
- Assist in execution of local and regional advisory board
- Ensure all activities executed with EEs are within the approved strategic communication
- Establish scientific collaboration and develop strong relation with selected top EEs in the country
- Demonstrate leadership in execution of medically owned activities
- Briefing and training Speakers
Medical Science Liaison Heart Failure and Metabolism
Boehringer
Jeddah
2020.10 - 2021.08
- Responsible for pre-launching and support in launching Empagliflozin's new indication in heart failure with reduced ejection fraction HFrEF
- Digital Champion for the medical affairs, responsible for creating digital channels between Boehringer Ingelheim and EEs for better understanding our customer behavior and more reachability
- Support E-Platforms across Therapeutic Areas and innovative programs
- Scout and suggest innovative e-programs and platforms for departmental function and therapeutic area development
Medical Science Liaison - Stroke
Boehringer Ingelheim
Jeddah
2019.02 - 2020.09
- Identifying Stroke centers and mapping them according to their readiness
- Improving quality of treatment in stroke center through identifying the gaps in each center by Simulations activity
- Setting Protocol for Stroke management in the hospitals
- Training all stroke team members: Neurologist, ER, Nurses, EMS and paramedics
- Ensure excellent in interaction with external stakeholders
- Key medical projects:
- CKD PATH (project with SSDS aimed on developing AI tool to enhance CKD diagnosis in Saudi Arabia)
- CKD consensus paper
- Saudi Heart Failure guidelines updating
- CKD Integrated Program (an educational program for the frontliners aimed improving CKD early diagnosis and treatment)
- CV risk management consensus paper for Saudi Arabia and gulf countries
Medical Representative
Boehringer Ingelheim
Riyadh
2017.03 - 2019.01
- Responsible for launching and promoting two new anti-diabetic products
- Jardiance and Synjardy in Riyadh
Medical Representative
Boehringer Ingelheim
Makka
2015.04 - 2017.02
- Responsible for launching and promoting new anti-diabetic product Trajenta in Makka and Taif Region
Medical Representative
Boehringer Ingelheim
Abha
2015.01 - 2015.04
- Responsible for launching new anti-diabetic Trajenta in whole south region
Medical Representative
AstraZeneca
Cairo
2013.10 - 2014.11
- Responsible for promoting Atacand and Imdur in Cairo center
Education
Bachelor of Pharmacy - Pharma
Cairo University
2008.01 - 2013.01
Skills
- Team building
- Communication skills
- Strategic planning
- Leadership
- Social media marketing
- Problem-solving
Websites
Timeline
Senior Medical Science Liaison
Boehringer Ingelheim
2025.03 - 2026.03
Phase III Clinical Trials in Saudi Arabia
Boehringer Ingelheim
2024.01 - 2026.03
Medical Advisor and Healthcare Compliance Manager
Boehringer Ingelheim
2024.01 - 2025.03
Key Medical projects
Company Name
2023.01 - 2026.03
Senior Medical Science Liaison
Boehringer Ingelheim
2021.09 - 2024.01
Medical Science Liaison Heart Failure and Metabolism
Boehringer
2020.10 - 2021.08
Medical Science Liaison - Stroke
Boehringer Ingelheim
2019.02 - 2020.09
Medical Representative
Boehringer Ingelheim
2017.03 - 2019.01
Medical Representative
Boehringer Ingelheim
2015.04 - 2017.02
Medical Representative
Boehringer Ingelheim
2015.01 - 2015.04
Medical Representative
AstraZeneca
2013.10 - 2014.11
Bachelor of Pharmacy - Pharma
Cairo University
2008.01 - 2013.01